InvestorsHub Logo
Followers 8
Posts 1890
Boards Moderated 0
Alias Born 05/05/2016

Re: mmbo post# 13901

Friday, 07/20/2018 12:05:37 PM

Friday, July 20, 2018 12:05:37 PM

Post# of 44784

my view is the overriding fear that a huge pharmaceutical will beat this company to the market and instantly crush share value. The Novartis news this morning is a case in point. Any dissenting opinions are welcome.



Please read my post #13896 this AM. A VERY STRONG dissenting opinion!

No need for any fear. I would also recommend the article by Zach Hartman, PhD. Here's the relevant exerpt:

"it should be emphasized that (Novartis's) eltrombopag is not likely to be a strong competitor (to Pluristem), since there is a lot more that needs to be done to repair the damage done by radiation."

I hope your fears have been allayed!

if not read my additional comments:

I see Novartis' interest as a POSITIVE! It shows that the target indications (multiple) represent a huge value. Pluristem will be there first and with a better product!


If you're still afraid do some research on PLX-R18 and the realization that a live cell, responding to the distress signals coming from the very cells that are in trouble, will be a more effective treatment option, your fears will subside. In fact I would say that PLX-R18 is a very good treatment for fears about BIG Novartis.